Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Maintenance Notification: On Saturday January 19th 2019 you will not be able to log into this website due to planned maintenance work.

If you have any questions or concerns, please feel free to reach out to your support team at clientservices@pharma.informa.com

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?

This article was originally published in The Pink Sheet Daily

19 Aug 2015
News

Executive Summary

With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Related Companies

Related Deals

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Regulation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS078823

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS078823

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?

News

Executive Summary

Related Content

A 'More Radical Idea': Set Expiration Dates For Priority Review Vouchers

Priority Review Voucher Crash: Spark's Sale To Jazz Lowest Price Since 2014

Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity

Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support

Sanofi/Regeneron’s PCSK9 Inhibitor Gets Reassuring CV Data – And A Priority Review Voucher

Topics

Related Companies

Related Deals

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert